Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Vesical Imaging-Reporting and Data System (VI-RADS) has been shown to be effective in diagnosing muscle invasion of bladder cancer (BC) in primary patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Purpose</h3><p>To evaluate the diagnostic efficacy of VI-RADS in a BC target population which included post-treatment patients, and to determine the repeatability.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Study Type</h3><p>Prospective.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Population</h3><p>Seventy-three patients (42 with primary BC, 31 with post-treatment BC).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Field Strength/Sequence</h3><p>3.0 T MRI with propeller fast spin-echo T<sub>2</sub>WI, echo planer imaging diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCEI). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Assessment</h3><p>VI-RADS scores were independently assessed by five radiologists with different levels of experience. The diagnostic efficiency in each group (primary and post-treatment) and of each radiologist was assessed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Statistical Tests</h3><p>Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and area under the curve (AUC) in receiver operating characteristic curve analysis were calculated to evaluate VI-RADS diagnostic performance. Interobserver agreement was assessed using weighted Kappa statistics. A <i>P</i> value <0.05 was considered statistically significant. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>At the corresponding cut-off, AUC values of three groups range from 0.936 to 0.947 and AUC values of five observers range from 0.901 to 0.963. There was no significant difference between the AUCs in the primary and post-treatment groups (<i>P</i> = 0.870). The cut-off of the whole group and the post-treatment group was ≥4, and the cut-off of the primary group was ≥3. The Kappa values of interobserver agreements range from 0.709 to 0.923. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>After expanding the target population to include post-treatment patients, VI-RADS still has good diagnostic efficacy and repeatability. VI-RADS could potentially be a preoperative staging tool for post-treatment patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Level of Evidence</h3><p>1</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Technical Efficacy Stage</h3><p>2</p></section>

The validity, reliability, and reviewer acceptance of VI-RADS in assessing muscle invasion by bladder cancer: a multicenter prospective study

The Additional Value of Tri-parametric MRI in Identifying Muscle-invasive Status in Bladder Cancer.

Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) Scoring System in Predicting Muscle Invasion of Bladder Cancer.

Multiparametric MRI-based VI-RADS: Can It Predict 1- to 5-Year Recurrence of Bladder Cancer?

Elaboration of a Multisequence MRI-based Radiomics Signature for the Preoperative Prediction of the Muscle-Invasive Status of Bladder Cancer: a Double-Center Study

Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients

Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy

Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in bladder cancer; is contrast material really necessary in detecting muscle invasion?

Pictorial review of the diagnosis of muscle-invasive bladder cancer using vesical imaging-reporting and data system (VI-RADS)

MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy

Diagnostic accuracy and discriminative power of biparametric versus multiparametric MRI in predicting muscle-invasive bladder cancer

Detection of Muscle-Invasive Bladder Cancer on Biparametric MRI Using Vesical Imaging-Reporting and Data System and Apparent Diffusion Coefficient Values (VI-RADS/ADC)

Comparison of the diagnostic performance of biparametric and multiparametric MRI in detecting muscle invasion of bladder cancer located at the ureteral orifice

Accuracy and Challenges in the Vesical Imaging‐Reporting and Data System for Staging Bladder Cancer

Preliminary Exploration of the Application of Vesical Imaging‐Reporting and Data System ( VI‐RADS ) in Post‐treatment Patients With Bladder Cancer: A Prospective Single‐Center Study

The value of VI-RADS combined with tumor contact length in the detection of muscle-invasive bladder cancer

Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach

Vesical Imaging-Reporting and Data System (VI-RADS) As a Grouping Imaging Biomarker Combined with a Decision-Tree Mode to Preoperatively Predict the Pathological Grade of Bladder Cancer.

Effect of accumulating experience on diagnostic performance of VI-RADS in bladder cancer

Combining Multiparametric MRI Radiomics Signature with the Vesical Imaging-Reporting and Data System (VI-RADS) Score to Preoperatively Differentiate Muscle Invasion of Bladder Cancer

Role of Additional MRI‐Based Morphologic Measurements on the Performance of VI‐RADS for Muscle‐Invasive Bladder Cancer